Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Mortensen

Showing results (301-310 of 385) with videos related to

Pageof 39
Sort By:
Blood|June 29, 2026
NSD2 Degradation Remediates the Oncogenic Cistrome in t(4;14) Multiple MyelomaBo Hu, Jacob Edwards, Hardik Modi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2013
The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomasBeatrice Gini, Ciro Zanca, Deliang Guo, et al.
Journal of Medicinal Chemistry|August 6, 2021
Discovery of the Selective Protein Kinase C-θ Kinase Inhibitor, CC-90005Patrick Papa, Brandon Whitefield, Deborah S Mortensen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2025
Discovery of BMS-986365, a first-in-class dual androgen receptor ligand-directed degrader (AR LDD) and antagonist, for the treatment of advanced prostate cancerSurendra Nayak, John D Norris, Massimo Ammirante, et al.
Journal of Medicinal Chemistry|February 11, 2026
Discovery of BMS-986458, a Potent and Selective B-Cell Lymphoma 6 Protein Ligand-Directed Degrader, for the Treatment of B-Cell Non-Hodgkin LymphomaDeborah S Mortensen, Hunter P Shunatona, Natalie Holmberg-Douglas, et al.
Diabetes, Obesity & Metabolism|July 29, 2025
The Steno 1 study: Multifactorial intervention to reduce cardiovascular disease in type 1 diabetes-rationale and protocol of the prospective, randomized, open-labelled multicentre studyElisabeth B Stougaard, Mads R Andersen, Jonatan I Bagger, et al.
Journal of Medicinal Chemistry|June 24, 2015
Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115Deborah S Mortensen, Sophie M Perrin-Ninkovic, Graziella Shevlin, et al.
Journal of Medicinal Chemistry|June 18, 2015
Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223Deborah S Mortensen, Sophie M Perrin-Ninkovic, Graziella Shevlin, et al.
Journal of Internal Medicine|February 13, 2013
Effects of an isocaloric healthy Nordic diet on insulin sensitivity, lipid profile and inflammation markers in metabolic syndrome -- a randomized study (SYSDIET)M Uusitupa, K Hermansen, M J Savolainen, et al.
Annals of the American Thoracic Society|July 29, 2022
Asthma and Wheeze Severity and the Oropharyngeal Microbiota in Children and AdolescentsJonathan Thorsen, Jakob Stokholm, Morten Arendt Rasmussen, et al.
Pageof 39

Showing results (301-310 of 385) with videos related to

Sort By:
Pageof 39
Blood|June 29, 2026
NSD2 Degradation Remediates the Oncogenic Cistrome in t(4;14) Multiple MyelomaBo Hu, Jacob Edwards, Hardik Modi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2013
The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomasBeatrice Gini, Ciro Zanca, Deliang Guo, et al.
Journal of Medicinal Chemistry|August 6, 2021
Discovery of the Selective Protein Kinase C-θ Kinase Inhibitor, CC-90005Patrick Papa, Brandon Whitefield, Deborah S Mortensen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2025
Discovery of BMS-986365, a first-in-class dual androgen receptor ligand-directed degrader (AR LDD) and antagonist, for the treatment of advanced prostate cancerSurendra Nayak, John D Norris, Massimo Ammirante, et al.
Journal of Medicinal Chemistry|February 11, 2026
Discovery of BMS-986458, a Potent and Selective B-Cell Lymphoma 6 Protein Ligand-Directed Degrader, for the Treatment of B-Cell Non-Hodgkin LymphomaDeborah S Mortensen, Hunter P Shunatona, Natalie Holmberg-Douglas, et al.
Diabetes, Obesity & Metabolism|July 29, 2025
The Steno 1 study: Multifactorial intervention to reduce cardiovascular disease in type 1 diabetes-rationale and protocol of the prospective, randomized, open-labelled multicentre studyElisabeth B Stougaard, Mads R Andersen, Jonatan I Bagger, et al.
Journal of Medicinal Chemistry|June 24, 2015
Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115Deborah S Mortensen, Sophie M Perrin-Ninkovic, Graziella Shevlin, et al.
Journal of Medicinal Chemistry|June 18, 2015
Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223Deborah S Mortensen, Sophie M Perrin-Ninkovic, Graziella Shevlin, et al.
Journal of Internal Medicine|February 13, 2013
Effects of an isocaloric healthy Nordic diet on insulin sensitivity, lipid profile and inflammation markers in metabolic syndrome -- a randomized study (SYSDIET)M Uusitupa, K Hermansen, M J Savolainen, et al.
Annals of the American Thoracic Society|July 29, 2022
Asthma and Wheeze Severity and the Oropharyngeal Microbiota in Children and AdolescentsJonathan Thorsen, Jakob Stokholm, Morten Arendt Rasmussen, et al.
Pageof 39